Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06774963 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by NextCure.

Recruiting
Registry status
Phase 1
Development phase
145
Enrollment target
14
Study locations

NCT06774963 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by NextCure. The registered enrollment target is 145 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 14 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06774963, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by NextCure.

RECRUITING
Registry status
Phase 1
Development phase
145 participants
Enrollment target
14
Study locations

Study Summary

This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

Conditions Studied

Breast Cancer Non-Small Cell Lung Cancer Ovarian Cancer Endometrial Cancer Biliary Tract Cancer Advanced or Metastatic Solid Tumors

Interventions

  • DRUG LNCB74

Study Locations (14)

Texas

  • MD Anderson - Houston
  • NEXT Oncology - San Antonio
  • UT Health San Antonio - MD Anderson Cancer Center - San Antonio

Pennsylvania

  • Sidney Kimmel Comprehensive Center at Jefferson - Philadelphia
  • UPMC - Pittsburgh

California

  • Hoag Family Cancer Institute - Newport Beach

Kentucky

  • St. Elizabeth Healthcare - Edgewood

Massachusetts

  • Dana Farber Cancer Institute - Boston

Missouri

  • Washington University, Siteman Cancer Center - St Louis

New Jersey

  • John Theurer Cancer Ctr at Hackensack Univ. Med Ctr. - Hackensack

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo

Trial Details

FieldValue
Enrollment Target 145 participants
Start Date 2025-01-07
Est. Completion 2026-12
Phase Phase 1

Sponsor

NextCure

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06774963

The ClinicalTrials.gov registry entry for NCT06774963 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is NextCure, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which LNCB74 is the first listed.

NCT06774963 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Texas, Pennsylvania, California.

Frequently Asked Questions

What is clinical trial NCT06774963 about?

NCT06774963 is a clinical study titled "A Phase 1 Study of LNCB74 in Advanced Solid Tumors". This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

What is the current status of trial NCT06774963?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2025-01-07. Estimated completion is 2026-12.

What conditions does trial NCT06774963 study?

This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Endometrial Cancer, Biliary Tract Cancer.

What interventions are being tested in trial NCT06774963?

The interventions under investigation include: LNCB74 (DRUG).

Who is sponsoring clinical trial NCT06774963?

This trial is sponsored by NextCure, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06774963 being conducted?

This trial has 14 study locations across California, Kentucky, Massachusetts, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Non-Small Cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.